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ABSTRACT
Inflammatory autoimmune diseases like Crohn’s Disease (CD) and Rheumatoid Arthritis (RA)
share some of the same single nucleotide polymorphisms (SNPs) in protein tyrosine phosphatase
non-receptor types 2 and 22 (PTPN2/22), which contribute to their pathogenesis. In clinical CD
and RA samples, PTPN2:rs478582 and PTPN22:rs2476601 were found to exacerbate a number
of inflammatory processes associated with CD and RA. To confirm the role of these SNPs in CD
and RA pathogenesis, CRISPR-Cas9 was used to induce the SNPs in T-cells. Cells were also
treated with the naturally occurring polyamine, spermidine, to restore PTPN2/22 function and
reverse the inflammatory effects of the SNPs. The PTPN2 SNP decreased PTPN2 expression by
3.2-fold and the PTPN22 SNP decreased PTPN22 expression by 2.4-fold compared to WT Tcells. Proliferation increased by 10.2-fold in PTPN2 SNP cells and 8.4-fold in the PTPN22 SNP
cells compared to WT cells. Both SNPs increased secretion levels IFN- and TNF-.
Additionally, 80.32% of PTPN2 SNP cells and 85.82% of PTPN22 SNP cells were activated
compared to 70.48% of WT T-cells. Spermidine treatment increased PTPN2/22 expression in all
cell types and was dose-dependent in cells with either SNP. Proliferation levels decreased by
approximately 5-fold in spermidine treated PTPN2 SNP cells and 3.1-fold in PTPN22 SNP cells
treated with 10 M of spermidine and 12.0-fold when treated with 20 M. IFN- and TNF-
secretion levels decreased with spermidine treatment in all cell groups. Lastly, T-cell activation
decreased to 51.39% of PTPN2 SNP cells and 46.36% of PTPN22 SNP cells when treated with
10 M of spermidine. These findings may explain the therapeutic response seen in CD and RA
patients prescribed polyamines. This study confirms the inflammatory role of the PTPN2/22
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SNPs and displays the anti-inflammatory and restorative property of spermidine for its potential
therapeutic use in CD and RA patients with genetic polymorphisms.

iv

Dedicated to my family who have always loved and supported me.
Thank you for always encouraging me to purse my dreams.

v

ACKNOWLEDGMENTS
I would like to thank my supervisor, Dr. Naser, for all of his support and guidance over the
course of my master’s degree. You pushed me to think critically during my research, and I am
grateful to have had you as my advisor. I would also like to acknowledge my committee
members, Dr. Masternak and Dr. Siddiqi. Thank you for all of your feedback and insights
throughout this process. Lastly, I would like to thank all members of the Naser lab for their
support, especially Dr. Ahmad Qasem for all of the training and assistance he provided. This
work was made possible by the Florida Legislative grant.

vi

TABLE OF CONTENTS
LIST OF FIGURES ....................................................................................................................... ix
LIST OF TABLES .......................................................................................................................... x
CHAPTER ONE: INTRODUCTION ............................................................................................. 1
CHAPTER TWO: MATERIALS AND METHODS ..................................................................... 9
CRISPR-Cas9 Transfection, Stimulation, and Treatment of T-cells .......................................... 9
Confirming Induction of PTPN2/22 SNPs ................................................................................ 10
Measurement of PTPN2/22 Expression in Treated T-cells ....................................................... 11
T-cell Proliferation Assay of Treated T-cells ............................................................................ 13
Measurement of IFN- and TNF- Secretion by Treated T-cells ............................................. 14
CD25 (IL-2RA) Fluorescent Immunostaining Assay ............................................................... 14
Statistical Analysis .................................................................................................................... 15
CHAPTER THREE: RESULTS ................................................................................................... 16
PTPN2/22 SNP Sequencing ...................................................................................................... 16
PTPN2/22 SNPs Decrease Their Corresponding Gene Expression Upon Induction in Jurkat Tcells Using CRISPR-Cas9 ......................................................................................................... 16
PTPN2/22 SNPs Increase T-cell Proliferation Upon PHA Induction in Jurkat T-cells Using
CRISPR-Cas9 ............................................................................................................................ 16

vii

PTPN2/22 SNPs Increase Pro-Inflammatory Cytokine Secretion Upon Induction in Jurkat Tcells Using CRISPR-Cas9 ......................................................................................................... 17
PTPN2/22 SNPs Increase T-cell Activation Upon Induction in Jurkat T-cells Using CRISPRCas9 ........................................................................................................................................... 17
Spermidine Increases PTPN2/22 Expression in CRISPR-Cas9-edited Jurkat T-cells with
PTPN2/22 SNPs ........................................................................................................................ 18
Spermidine Decreases T-cell Proliferation in CRISPR-Cas9-edited Jurkat T-cells with
PTPN2/22 SNPs ........................................................................................................................ 19
Spermidine Decreases Pro-Inflammatory Cytokine Secretion in CRISPR-Cas9-edited Jurkat Tcells with PTPN2/22 SNPs ........................................................................................................ 20
Spermidine Decreases T-cell Activation in CRISPR-Cas9-edited Jurkat T-cells with PTPN2/22
SNPs .......................................................................................................................................... 21
CHAPTER FOUR: DISCUSSION ............................................................................................... 22
APPENDIX A: FIGURES ............................................................................................................ 27
APPENDIX B: TABLES .............................................................................................................. 34
APPENDIX C: CONSENT FOR PUBLICATION ...................................................................... 39
LIST OF REFERENCES .............................................................................................................. 40

viii

LIST OF FIGURES
Figure 1: Alignment of PTPN22 SNP region in CRISPR-Cas9-edited Jurkat T-cells with
PTPN22 SNP to Wild-type PTPN22 SNP region. ........................................................................ 28
Figure 2: Effect of PTPN2/22 SNPs on their corresponding gene expression in CRISPR-Cas9edited Jurkat T-cells. ..................................................................................................................... 28
Figure 3: Effect of PTPN2/22 SNPs on proliferation in CRISPR-Cas9-edited Jurkat T-cells
stimulated with PHA. .................................................................................................................... 29
Figure 4: Effect of PTPN2/22 SNPS on CD25 (IL-2RA) expression in CRISPR-Cas9-edited
Jurkat T-cells stimulated with PHA. ............................................................................................. 30
Figure 5: Effect of spermidine on PTPN2 expression in WT and PTPN2 SNP T-cells stimulated
with PHA ...................................................................................................................................... 31
Figure 6:Effect of spermidine on PTPN22 expression in WT and PTPN22 SNP T-cells
stimulated with PHA ..................................................................................................................... 31
Figure 7: Effect of spermidine on proliferation in CRISPR-Cas9-edited Jurkat T-cells stimulated
with PHA. ..................................................................................................................................... 32
Figure 8: Effect of spermidine on CD25 (IL-2RA) expression in CRISPR-Cas9-edited Jurkat Tcells stimulated with PHA. ........................................................................................................... 33

ix

LIST OF TABLES
Table 1: List of SNPs examined in this study. .............................................................................. 35
Table 2: Synthetic single-guide RNA and donor DNA sequences ............................................... 36
Table 3: RT-qPCR primer sequences for tested genes ................................................................. 37
Table 4: Effect of PTPN2/22 SNPs on IFN- and TNF- secretion in CRISPR-Cas9-edited
Jurkat T-cells stimulated with PHA .............................................................................................. 37
Table 5: Effect of spermidine on IFN- and TNF- secretion in CRISPR-Cas9-edited Jurkat Tcells stimulated with PHA. ........................................................................................................... 38

x

LIST OF ABBREVIATIONS
CD: Crohn’s Disease
ICAM-1: Intracellular Adhesion Molecule-1
IFN-: Interferon gamma
MAPK: Mitogen-activated Protein Kinase
NCBI: National Center for Biotechnology Information
NF-kB: Nuclear Factor-B
NOD2: Nucleotide-binding Oligomerization Domain-containing Protein-2
PBS: Phosphate-buffered Saline
PCR: Polymerase Chain Reaction
PFA: Paraformaldehyde
PHA: Phytohemagglutinin
RA: Rheumatoid Arthritis
RT-qPCR: Quantitative Reverse Transcription Polymerase Chain Reaction
sgRNA: Single-guide RNA
SNPs: Single Nucleotide Polymorphisms
SPD: Spermidine
TCR: T-cell Receptor
TNF-: Tumor Necrosis Factor alpha
WT: Wild-type

xi

CHAPTER ONE: INTRODUCTION
Autoimmune diseases have previously been defined as an activation of either T-cells or
B-cells, or a combination of the two, without the presence of a continuing infection or another
apparent cause [1]. Although majority of autoimmune diseases are rare individually, excluding
rheumatoid arthritis (RA) and autoimmune thyroiditis, when examined together approximately
5% of the population in Western countries is affected by some autoimmune disease [1-3]. More
specifically, in the United States more than 3% of the population has an autoimmune disease [2].
Majority of autoimmune diseases disproportionately affect women and are among the leading
causes of death in women under the age 65 years in the United States [2-3]. Due to their chronic
disposition, autoimmune diseases have a substantial effect on the use of medical care, direct and
indirect economic coasts, as well as quality of life with high effects on mortality and morbidity
[2]. Clinically, autoimmune diseases are classified as either systemic or organ-specific, however,
this classification does not account for the variation in causation [1,3]. An improved
classification identifies disorders based on a change in T-cell or B-cell selection, regulation, or
death or based on autoimmunity cause by an anomalous response to a certain foreign or selfantigen [1]. This division allows for improved selection of therapeutic agents based on the
pathogenic mechanism of the autoimmune disease [1]. Unfortunately, this classification system
is limited to use with animal models as human diseases are difficult to determine whether they
are the result of an abnormality in lymphocyte function or antigen specificity [1].
Genetic factors play an important role in susceptibility to autoimmune disorders. Some
result from a mutation in a single gene, but majority are due to the interplay of multiple
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susceptibility genes [1]. Some of these genetic anomalies are seen in normal immune function
but when combined with additional susceptibility markers promote autoimmunity [4-5]. More
than 200 genetic loci have been linked to autoimmune diathesis, majority of them being involved
in innate immune response, cytokine signaling, or lymphocyte activation [3]. These mice models
along with human genetic studies showed that many autoimmune diseases share pathogenic
pathways such that genetic alterations can lead to predisposition to multiple disorders indicating
the potential to treat various disorders with the same therapeutic agents [1]. In most cases,
autoimmunity is the result of a combination genetic and environmental factors [1,3,6].
Environmental factors include tobacco smoke, radiation, ultraviolet (UV) radiation, chemical
compounds, and infectious agents, among others [3]. One potential mechanism by which
environmental factors can induce autoimmunity is via epigenetic changes either directly or
indirectly which modulate gene expression thereby changing immune cell function [3]. Another
mechanism involves the production of novel antigenic molecules upon reaction of chemical
products with self-components in the body [7]. In the case of UV radiation, the profusion and
localization of autoantigens can be altered [8]. Furthermore, nearly all autoimmune diseases have
been linked to at least one infectious agent [6]. Microbial agents can induce autoimmunity via
polyclonal activation, release of sequestered antigens, or a cross-reaction between environmental
and self-antigens due to molecular mimicry [1,3,6]. With molecular mimicry, lymphocytes can
initially be activated by an infectious agent and then sustained by autoantigens after eradication
of the infection [1]. As such, many autoimmune diseases are associated with an abnormal
inflammatory response that continues, leading to severe tissue and organ damage [9].
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Therapeutic approached for autoimmune diseases include altering thresholds of immune
activation, modulation of antigen-specific cells, reconstitution of the immune system by stem cell
transplantation, and sparing of target organs [1]. To alter threshold of immune activation,
costimulatory factors, cytokines, and signaling cascades are targeted to alter the availability of
proteins involved in intracellular signaling thereby redirecting the immune system away from
autoimmunity [1]. For antigen-specific therapies, success has been seen in animal models, where
exposing the immune system to autoantigens or specific peptides has been shown to induce
tolerance [1]. The third therapeutic approach, stem cell transplantation, aims to restore
homeostasis with regulatory cells [1]. Lastly, treatments for sparing target organs involve antiinflammatory agents, targeting of chemokines, and regulation of matrix metalloproteases and
nitric oxide synthase [1].
Our first autoimmune disease of interest, Crohn’s Disease (CD), is a chronic
inflammatory disease that affects the entire gastrointestinal tract with the most commonly
affected segments being the terminal ileum and the colon [10]. Symptoms of CD can include
fever, diarrhea, and weight loss which can be attributed to ulcer formation in the mucosa [11].
CD is characterized as a progressive and destructive inflammatory bowel disease (IBD) where
nearly half of patients have systemic, extraintestinal manifestation which can affect quality of
life including risk of hospitalization, complications, and surgeries [12]. The incidence of CD, 0.1
to 58 cases per 100,000 person-years, has been steadily increasing worldwide with greater
incidence and prevalence in developed countries and urban areas compared to developing
countries and rural areas [12-13]. The highest prevalence of CD is in Europe, Canada, and the
United States where there are approximately 319 to 322 cases per 100,000 people [12-14]. While
3

there is still uncertainty of the cause of CD, there is extensive research linking genetic,
environmental, and immunological factors to the risk of disease onset and progression [10-11,1516]. Genome-wide association studies have identified over 200 genetic loci linked to an
increased risk of developing CD [12]. These include single nucleotide polymorphisms (SNPs) in
NOD2 (CARD15), ATG16L1, IL23R, TNFSF15, PTPN2, and PTPN22 [12,16-19].
Environmental risk factors include smoking, altered gut microbiota resulting from a low fiber
and high carbohydrate diet, medications such as oral contraceptives, aspirin, and non-steroidal
anti-inflammatory drugs (NSAIDs), as well as Mycobacterium avium subspecies
paratuberculosis (MAP) which was found in blood and breast milk of CD patients [12,19-22].
The abnormal inflammatory response associated with CD is the result of persistent T-cell
immune activation, increased production and secretion of pro-inflammatory cytokines such as
IFN- and TNF-, and hyperproliferative T-cells [12,17-18].
Current therapeutic agents for CD are administered based on the disease severity and the
previous therapy responses [10,12,19]. The most commonly used therapeutic agents are
NSAIDs, corticosteroids such as glucocorticoids, immunosuppressants such as thiopurines and
methotrexate, biologics such as anti-TNF agents, and anti-adhesion molecules such as
vedolizumab [10,12,19]. Surgery is used under severe circumstances of refractory CD with
medical complications including abscesses, malignancies, or lack of response to treatment and is
required in nearly two-thirds of CD patients [10,19]. Treatment for CD is typically life-long,
requiring continuous administration of the agents which can have many adverse side effects in
patients [13]. For example, continuous use of NSAIDs and glucocorticoids can lead to ulceration,
osteoporosis, hypertension, and weight gain among others [23-26].
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The next disease of interest, Rheumatoid Arthritis (RA), is classified as an idiopathic
autoimmune disease characterized by severe inflammation that leads to joint swelling and
destruction of bone and cartilage [15,17]. Like CD, RA incidence has also been increasing with
approximately 1% of the world’s population being affected by RA and its prevalence being 0.51% in Europe and North America [27]. Of even greater concern is the increased mortality and
premature death associated with RA [27]. RA has also been shown to have genetic and
environmental triggers. Genetic risk factors include SNPs in HLA-DR1, HLA-DR4, PTPN2, and
PTPN22 [17,28]. Environmental factors include smoking, alcohol, and infectious agents such as
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans (Aa), Epstein-Barr virus
(EBV), and MAP [17,28-29]. Together, these factors contribute to the severe inflammatory
pathogenesis of RA which is also characterized by excessive production and secretion of the proinflammatory cytokines, IFN- and TNF-, as well as hyperproliferative and hyperactive T-cells
[17,30-31].
Traditional RA treatments are disease-modifying antirheumatic drugs (DMARDs) such
as methotrexate [22]. However, patients with moderate to severe RA may not respond to these
treatments. As such, a new class of RA therapeutics known as biological drugs is used; anti-TNF,
IL-1 and IL-6 antagonists, anti-CD28, and anti-B cell agents [22]. Similar to therapies for CD,
RA treatments have a number of associated side effects such as gastrointestinal (GI) intolerance,
hypersensitivity to the medication, production of antibodies against the medication, and an
increased risk of developing opportunistic infections, particularly mycobacterial infections
[25,33-34]. Consequently, there is a need for safer and more effective therapies for patients with
inflammatory autoimmune diseases.
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Two genes have recently been identified to be involved in multiple inflammatory and
autoimmune diseases [16,35-37]. Important in T-cells, PTPN2 and PTPN22 (protein tyrosine
phosphatase nonreceptor types 2 and 22) encode enzymes that negatively regulate T-cell receptor
(TCR) signaling by dephosphorylating and inactivating associated kinases and substrates [16,3537]. This limits the immune response to an antigen and blocks spontaneous activation of T-cells.
Two SNPS, one in PTPN2 (rs478582-C) and the other in PTPN22 (rs2476601-A) have been
linked to a potential increased risk of developing CD and RA (Table 1) [17-18]. The PTPN2
SNP was found in 83% of CD samples and 79% of RA samples compared to about 60% of
healthy controls while the PTPN22 SNP was present in 16% of CD patients and 29% of RA
patients in comparison to only 6% of healthy controls [17-18]. PTPN2:rs478582-C occurs within
intron 3 and results in a thymine being changed to a cytosine which is speculated to cause
problems during RNA splicing and cause a loss of the protein’s activity upon completion of
translation [17,38-41]. PTPN22:rs2476601-A is located in exon 14 and is a base change from a
guanine to an adenosine resulting in the arginine amino acid residue at position 620 to be
changed to a tryptophan [16-18]. This change is within the catalytic portion of the PTPN22
protein and has been theorized to also decrease the protein’s activity [17,38-42]. In clinical CD
and RA samples, these SNP mutations led to decreased expression of their corresponding genes,
overexpression of the pro-inflammatory cytokine IFN-, and increased T-cell proliferation
indicating their possible role in the pathogenesis of inflammatory autoimmune diseases [17-18].
These findings, however, have not yet been confirmed in vitro.
Furthermore, there is a need for therapies that are safer and more effective in CD and RA
patients with and without genetic anomalies. Recent research has investigated the effect of
6

treating human intestinal epithelial cells with the PTPN2:rs1893217-G SNP that is a risk factor
for IBD with different polyamines [43]. They found the natural occurring polyamine,
spermidine, was most effective in increasing PTPN2 expression and activating its phosphatase
activity, as well as reducing STAT1 and STAT3 phosphorylation by IFN- which indicates its
ability to suppress pro-inflammatory signaling cascades [43]. Spermidine treatment also
decreased expression of the pro-inflammatory cytokine, IFN- and its pro-inflammatory target
genes, ICAM-1 and NOD2 [43]. These effects were also found to be greater in cells with the
PTPN2:rs1893217-G SNP compared to wild-type cells [43]. Another study investigated
spermidine’s ability and mechanism in treating acute colitis in mice [44]. In the colitis models,
spermidine was found to reduce the disease activity index (DAI), reduce colonic inflammation,
and increase colonic length [44]. Furthermore, Pro-inflammatory cytokine expression, NF-B
(nuclear factor-B) and MAPK (mitogen-activated protein kinase) phosphorylation, and
activation of macrophages and T-cells in the colon decreased with pre- and post-treatment of
spermidine [44]. In inflamed colons and a mouse macrophage cell line, there was upregulation of
anti-inflammatory M2 macrophage markers and downregulation of pro-inflammatory M1
markers with spermidine treatment [44]. Additionally, LPS/TNF--induced inflammation
decreased with spermidine treatment in Caco-2 cells [44]. These findings provide strong
evidence for the potential use of spermidine as a therapeutic agent for IBD due to its ability to
ameliorate colonic inflammation in mice with acute colitis [44].
The present study aimed to confirm the role of the PTPN2:rs478582-C and
PTPN22:rs2476601-A SNPs in the inflammatory pathogenesis associated with Crohn’s disease
and Rheumatoid arthritis. It also aimed to investigate the anti-inflammatory effects of spermidine
7

for its potential therapeutic use in autoinflammatory immune disease patients with genetic
anomalies.
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CHAPTER TWO: MATERIALS AND METHODS
CRISPR-Cas9 Transfection, Stimulation, and Treatment of T-cells
The Jurkat T-cell cell line (ATCC TIB-152) was cultured in RPMI-1640 medium (ATCC
30-2001) with 10% fetal bovine serum (FBS; Sigma Life Science, St. Louis, MO, USA). Cells
were maintained in a humidified 5% CO2 incubator at 37°C and grown to confluency in cell
culture flasks. A total of 2.0 mL of cell suspension were transferred to 12-well tissue culture
plates with 8×104 cells per well. Donor DNA duplex was prepared by mixing the donor DNA
with its reverse complement (see Table 2) in a 1:1 molar ratio in a microcentrifuge tube and then
diluting the mixture to a final concentration of 1 pmol/L with a Tris buffer containing salt – 10
mM Tris, 1 mM EDTA, 50 mM NaCl (pH 8.0). The tube was incubated in a heating block at
95°C for 5 minutes and the temperature was then gradually reduced until room temperature was
reached. In a 2.0 mL microcentrifuge tube (Tube 1), 100 L of Opti-MEM I Reduced Serum
Medium (Thermo Fisher Scientific, Waltham, MA, USA), 5.0 g of TrueCut Cas9 Protein v2
(Thermo Fisher Scientific, Waltham, MA, USA), 1.0 g of TrueGuide Synthetic single-guide
RNA (sgRNA; see table 2; Thermo Fisher Scientific, Waltham, MA, USA), 10 L of Cas9 Plus
Reagent (Thermo Fisher Scientific, Waltham, MA, USA), and 1.0 g of donor DNA duplex (see
table 2; Thermo Fisher Scientific, Waltham, MA, USA) were mixed. In another 2.0 mL
microcentrifuge tube (Tube 2), 100 L of Opti-MEM I Reduced Serum Medium and 6 L of
Lipofectamine CIRSPRMAX Transfection Reagent (Thermo Fisher Scientific, Waltham, MA,
USA) were mixed and the solution from Tube 1 was immediately added to Tube 2. After mixing
the combined solution, the CRISPR transfection complex was incubated at RT for 5-10 min.

9

Cells were then left untreated or treated with 200 L of either the PTPN2 SNP or PTPN22 SNP
CRISPR transfection complexes. Cells were incubated for 3 days before being transferred to a
cell culture flask and grown to confluency. A total of 2.0 mL of cell suspension (Wild-type
(WT), PTPN2 SNP, and PTPN22 SNP T-cells) were transferred to 12-well tissue culture plates
with 2×105 cells per well and incubated with either RPMI only or 10 g/mL phytohemagglutinin
(PHA; Sigma Life Science, St. Louis, MO, USA), and concurrently treated with 0, 10, or 20 M
of spermidine 99% (GC) (SPD; Sigma-Aldrich, St. Louis, MO, USA) for 72 h, before being
subject to further testing.

Confirming Induction of PTPN2/22 SNPs
DNA was isolated from WT, PTPN2 SNP, or PTPN22 SNP T-cells using the DNeasy
Blood and Tissue DNA isolation Kit (QIAGEN, Germantown, MD, USA). Briefly, 2 mL of each
cell culture was centrifuged at 2,500 rpm for 5 min before resuspending the pellets in 200 L of
PBS. Next, 20 L of Proteinase K was added to each sample followed by 200 L of Buffer AL.
The tubes were mixed thoroughly by vortexing and then incubated for 10 min at 56°C. Then, 200
L of 100% ethanol were added to each sample and mixed via vortexing. Each mixture was then
added to a DNeasy Mini spin column placed in a 2 mL collection tube before being centrifuged
for 1 min at 8,000 rpm. The flow-throughs and collection tubes were discarded while the spin
columns were placed in new 2 mL collection tubes and had 500 L of Buffer AW1 added to
them. After centrifuging again at 8,000 rpm for 1 min, flow-throughs and collection tubes were
discarded and spin columns were added to new 2 mL collection tubes. Next, 500 L of Buffer
AW2 were added to the spin columns before centrifuging for 3 min at 14,000 rpm and discarding
10

the flow-throughs and collection tubes. The spin columns were then placed in a clean 1.5 mL
microcentrifuge tube and had 200 L of Buffer AE added directly to their membranes. After
incubating at RT for 1 min, they were centrifuged for 1 min at 8,000 rpm to elute DNA. DNA
concentrations were measured using NanoDrop (OD at 260 nm). Polymerase Chain Reaction
(PCR) was then used to amplify the PTPN2/22 SNP regions using 25 L of PCR Master Mix
(2X) (Promega, Madison, WI, USA), 15 L of DNA, and 2 L of the forward and reverse PCR
primers for the PTPN2 or PTPN22 SNP regions (Eurofins Scientific, Luxemberg) (Table 2). To
conduct the PCR reactions for 30 cycles of: 1 min at 94°C, 2 min at 54°C, and 3 min at 72°C, the
MyGene Series Peltier Thermal Cycler was used. PCR samples were then run for 1 h in a 1.5%
agarose gel electrophoresis with ethidium bromide to confirm amplification between 300 and
400 bp using 15 L of PCR product mixed with 5 L of 6X DNA Loading Dye (Thermo Fisher
Scientific, Waltham, MA, USA). The NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel,
Bethlehem, PA, USA) was used to extract and purify DNA from the agarose gel according to
manufacturer’s protocol and DNA was quantified again via NanoDrop (OD at 260 nm) before
sending the samples to GENEWIZ for Sanger Sequencing. Sequences were aligned to WT
PTPN2/22 sequences obtained from NCBI (National Center for Biotechnology Information).

Measurement of PTPN2/22 Expression in Treated T-cells
Isolated RNA was reverse-transcribed into cDNA and then used in reverse transcription
PCR (RT-qPCR) to determine gene expression levels using primers specific to GAPDH, PTPN2,
and PTPN22 obtained from Invitrogen (Carlsbad, CA, USA) (Table 3). For RNA isolation, 2.0
mL of treated cells were centrifuged at 2,500 rpm for 5 min at 4°C and the pellets were
11

resuspended in 500 L of TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and left at RT for 5
min. Then, 125 L of chloroform was added to each sample and vortexed followed by another 5
min incubation at RT. The samples were centrifuged at 10,000 rpm for 5 min at 4°C and the
upper clear aqueous layers containing RNA were transferred to new 2.0 mL microcentrifuge
tubes. Next, each sample was gently mixed with 275 L of 100% isopropanol, incubated for 5
min at RT, and centrifuged at 14,000 rpm for 20 min at 4°C. The samples were then placed on
ice, the isopropanol was poured off, and 500 L of 75% ethanol in DEPC-treated water was
added. Then, the samples were centrifuged once more at 9,500 rpm for 5 min at 4°C before
pouring off the ethanol and leaving the pellets to air-dry for 10 min. Lastly, 15 L of DEPCtreated water was added to each tube and mixed gently. RNA concentrations were measured
using NanoDrop (OD at 260 nm). cDNA was then synthesized from 800 ng of each RNA
sample, 4 L of iScript reverse transcription supermix (BioRad, Hercules, CA, USA), and
topped up to a total volume of 20 L with RNase-free water. MyGene Series Peltier Thermal
Cycler was used to conduct the reactions for 5 min at 25°C, 20 min at 46°C, and 1 min at 95°C.
cDNA samples were either used immediately afterwards for RT-qPCR analysis or stored at 20°C. For RT-qPCR, each sample was mixed with 10 L of Fast SYBR Green Master Mix
(Thermo Fisher Scientific, Waltham, MA, USA), 1 L of forward primer, 1 L of reverse primer
(see Table 3), and 7 L of DEPC-treated water. Samples were plated in triplicate in a 96-well
microamp RT-PCR reaction plate and the 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) was used to run the experiment. GAPDH was used as a
control to obtain baseline CT values and gene expression of PTPN2 and PTPN22 were measured.

12

Relative gene expression levels were calculated using: (2−∆CT) × 1000, where ∆CT = CTsample –
CTGAPDH.

T-cell Proliferation Assay of Treated T-cells
In a 96-well culture plate, 100 L aliquots of 2×105/mL of cell suspension (WT, PTPN2
SNP, or PTPN22 SNP T-cells) were plated per well and incubated with 10 g/mL PHA and
concurrently treated in triplicate with 0, 10, or 20 M of SPD. The cells were incubated in a
humidified 5% CO2 incubator at 37°C for 48 h. The bromodeoxyuridine (BrdU) labeling
proliferation ELISA kit was used to perform the T-cell proliferation assay according to
manufacturer’s protocol (Abcam, Cambridge, UK). T-cells were labeled with 20 L of 1X BrdU
and incubated an additional 24 h under the same conditions. Next, 200 L of fixing solution was
added to each well and incubated at RT for 30 min. The plate was washed 3 times with 1X wash
buffer before adding 100 L of anti-BrdU monoclonal detector antibody to each well and
incubating the plate at RT for 1 h. Then the plate wash was repeated and 100 L of 1X
peroxidase goat anti-mouse IgG conjugate was added to each well and incubated for 30 min at
RT. After a final wash step, 100 L of TMB peroxidase substrate was added to each well and the
plate was incubated 30 min in the dark at RT. Finally, 100 L of stop solution was added to each
well and absorbance was read at 450 nm using a spectrophotometric microtiter plate reader.
Relative T-cell proliferation of samples was compared to WT T-cells stimulated with PHA and
were determined by calculating the fold change in absorbance readings at 450 nm.
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Measurement of IFN- and TNF- Secretion by Treated T-cells
Following 72 h incubation with PHA and spermidine treatment (0, 10, and 20 M), WT,
PTPN2 SNP, and PTPN22 SNP T-cells were pelleted via centrifugation at 2,500 rpm for 5 min at
4°C. Supernatants were saved and IFN- and TNF- protein secretion levels were determined
using the ELLA fully automated ELISA and its Simple Plex analyte cartridges for human IFN-
3rd generation and TNF- 2nd generation (ProteinSimple, San Jose, CA, USA) according to
manufacturer’s instructions. All groups were tested in duplicate.

CD25 (IL-2RA) Fluorescent Immunostaining Assay
CD-25 fluorescent immunostaining was performed on WT, PTPN2 SNP, and PTPN22
SNP T-cells following PHA stimulation and 10 M of SPD treatment for 72 h. Cells were fixed
with 4% paraformaldehyde (PFA) for 30 min. After washing with cold PBS, the cells were
blocked with 100 L of 10% Goat Serum – PBS with Normal Goat Serum (Thermo Fisher
Scientific, Waltham, MA, USA) – for 1 h at 25°C. Next, 100 L of CD25 Monoclonal Antibody
(IL2R.1) (Invitrogen, Carlsbad, CA, USA) diluted 1:10 in 10% Goat Serum was added to the
cells and incubated wrapped in aluminum foil in a dark fridge overnight. In the dark, Goat antiMouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488
(Invitrogen, Carlsbad, CA, USA) was diluted to 10 g/mL in PBS, then 100 L was added to the
cells and incubated for 1 h at 25°C. Cell were washed with cold PBS, and nuclei were then
stained using 60 L VECTASHIELD Antifade Mounting Medium containing 4′,6-diamidino-2phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA). Lastly, slides were examined
under the AmScope IN480TC-FL-MF603 Fluorescence Microscope, where green staining
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indicated CD25 expression and blue staining represents nuclei. The NIH Image J 1.39o software
(Rockville, MD, USA) was then used to generate merged images and the number of cells
expressing CD25 and total number of cells were counted and used to calculate the percentage of
CD25-expressing cells.

Statistical Analysis
To analyze data statistics, GraphPad Prism V.7.02 (GraphPad, La Jolla, CA, USA) was
used. The unpaired two-tailed t-test was used to determine significance of all data excluding
immunostaining data which were subject to the z-test. Data are expressed as average ± SD of the
mean and the difference between controls and samples was considered statistically significant at
a p value < 0.05 and at 95% confidence interval (CI).
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CHAPTER THREE: RESULTS
PTPN2/22 SNP Sequencing
Sequencing of the PTPN22 SNP region in PTPN22 SNP cells showed about 33%
difference from the WT PTPN22 gene indicated by the red lettering (Figure 1). Genotyping and
sequencing of the PTPN2 SNP region are ongoing and the results are still pending.

PTPN2/22 SNPs Decrease Their Corresponding Gene Expression Upon Induction in Jurkat Tcells Using CRISPR-Cas9
The effects of the SNPs, PTPN2:rs478582-C and PTPN22:rs2476601-A, on their
corresponding gene expression was tested in T-cells 72 hours after transfection with CRISPRCas9 and donor DNA (Figure 2). The results indicate that in the presence of the PTPN2 SNP,
expression of PTPN2 is significantly reduced (Figure 2A). PTPN2 expression was 3.2-fold lower
in PTPN2 SNP cells compared to WT T-cells (3.12 ± 0.332 and 10.0 ± 0.366, respectively).
Similar effects were seen for the PTPN22 SNP, where its presence resulted in a significant
reduction in PTPN22 expression (Figure 2B). PTPN22 SNP cells had 2.4-fold lower expression
of PTPN22 compared to WT T-cells (4.09 ± 0.567 and 10.0 ± 2.35, respectively).

PTPN2/22 SNPs Increase T-cell Proliferation Upon PHA Induction in Jurkat T-cells Using
CRISPR-Cas9
The effects of the SNPs, PTPN2:rs478582-C and PTPN22:rs2476601-A, were examined
on the proliferation of PHA-stimulated T-cells (Figure 3). T-cell proliferation was significantly
greater in PTPN2 and PTPN22 SNP cells compared to WT T-cells. Proliferation levels of T-cells
with the PTPN2 SNP increased by 10.2-fold relative to WT cells (10.2 ± 1.64 and 1.00 ± 0.124,
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respectively) (Figure 3A). Likewise, the PTPN22 SNP increased proliferation levels by 8.4-fold
in comparison to WT cells (8.42 ± 0.896 and 1.00 ± 0.124, respectively) (Figure 3B).

PTPN2/22 SNPs Increase Pro-Inflammatory Cytokine Secretion Upon Induction in Jurkat T-cells
Using CRISPR-Cas9
To measure the effects of the PTPN2:rs478582-C and PTPN22:rs2476601-A SNPs on
secretion of the pro-inflammatory cytokines, IFN- and TNF-, by PHA-stimulated T-cells, a
fully automated ELISA was used. IFN- and TNF- secretion levels were significantly increased
in PTPN2 and PTPN22 SNP T-cells compared to WT cells (Table 4). Specifically, IFN-
secretion by WT cells were 0.029 ± 0.003 pg/mL compared to PTPN2 and PTPN22 SNP cells
with 0.060 ± 0.004 pg/mL and 0.054 ± 0.002 pg/mL, respectively (Table 4). Similar trends were
seen for TNF- secretion with WT cells having 0.293 ± 0.042 pg/mL, PTPN2 SNP cells with
0.507 ± 0.014 pg/mL, and PTPN22 SNP cells with 0.408 ± 0.039 pg/mL (Table 4).

PTPN2/22 SNPs Increase T-cell Activation Upon Induction in Jurkat T-cells Using CRISPRCas9
Fluorescent immunostaining of CD-25 (IL-2RA) was used on PHA-stimulated T-cells to
determine the effects of the PTPN2:rs478582-C and PTPN22:rs2476601-A SNPs on T-cell
activation as seen in Figure 4 where blue staining indicates nuclei of cells and green staining
represents CD25 expression on the cell surface. The assay showed significantly more cells
expressing CD25 (IL-2RA) in the PTPN2 and PTPN22 SNP cell groups (80.32 ± 2.6% and 85.82
± 0.8%, respectively) compared to WT T-cells (70.48 ± 1.4%), thus indicating greater T-cell
activation levels in those cell groups (Figure 4A,B).
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Spermidine Increases PTPN2/22 Expression in CRISPR-Cas9-edited Jurkat T-cells with
PTPN2/22 SNPs
Figures 5 and 6 depict the effect of spermidine treatment (10 and 20 M) on PTPN2/22
expression in WT, PTPN2:rs478582-C, and PTPN22:rs2476601-A SNP T-cells as determined
via RT-qPCR. In unstimulated WT T-cells, 10 M of spermidine significantly increased PTPN2
and PTPN22 expression (5.65 ± 0.604 and 1.53 ± 0.165, respectively) relative to PTPN2/22
expression in untreated WT cells (1.00 ± 0.018 and 1.00 ± 0.013, respectively) (Figures 5A and
6A). PTPN2/22 expression was further increased significantly with 20 M of spermidine (9.06 ±
1.26 and 3.39 ± 0.352, respectively) (Figures 5A and 6A). Relative to PTPN2 expression in
PHA-stimulated WT T-cells not treated with spermidine (3.61 ± 0.512), PTPN2 expression was
significantly increased with 10 and 20 M of spermidine (6.56 ± 1.16 and 9.98 ± 0.430,
respectively) (Figure 5A). Although PTPN22 expression in PHA-stimulated WT T-cells
increased with 10 and 20 M of spermidine (19.6 ± 1.49 and 52.6 ± 5.38, respectively), the
increase was only significant with 20 M compared to PHA-stimulated WT T-cells with no
spermidine (7.08 ± 0.162) (Figure 6A). Spermidine significantly increased PTPN2 expression in
unstimulated and PHA-stimulated PTPN2 SNP cells in a dose-dependent manner (Figure 5B). In
comparison to PTPN2 expression in unstimulated PTPN2 SNP T-cells not treated with
spermidine (1.00 ± 0.020), those treated with 10 and 20 M of spermidine had expression
increase to 6.19 ± 1.51 and 14.9 ± 0.354, respectively (Figure 5B). The same was seen for
PTPN2 expression in PHA-stimulated PTPN2 SNP cells treated with 10 and 20 M of
spermidine (13.8 ± 1.16 and 15.9 ± 1.46, respectively) when compared to PHA-stimulated
PTPN2 SNP cells alone (3.01 ± 0.111) (Figure 5B). Spermidine treatment also significantly
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increased PTPN22 expression in unstimulated and PHA-stimulated PTPN22 SNP T-cells in a
dose-dependent manner (Figure 6B). Relative to PTPN22 expression in unstimulated PTPN22
SNP cells with no spermidine treatment (1.00 ± 0.038), 10 and 20 M of spermidine increased
expression to 2.46 ± 0.064 and 2.57 ± 0.383, respectively (Figure 6B). Similarly, PTPN22
expression increased to 2.70 ± 0.044 with 10 M of spermidine and 3.22 ± 0.051 with 20 M of
spermidine in PTPN22 SNP cells compared to untreated PHA-stimulated PTPN22 SNP cells
(2.04 ± 0.233) (Figure 6B).

Spermidine Decreases T-cell Proliferation in CRISPR-Cas9-edited Jurkat T-cells with PTPN2/22
SNPs
The effect of spermidine (10 and 20 M) was examined on T-cell proliferation in PHAstimulated WT, PTPN2:rs478582-C, and PTPN22:rs2476601-A SNP T-cells (Figure 7).
Spermidine did not have any effect on WT T-cell proliferation levels at 10 nor 20 M (2.04 ±
0.344 and 0.847 ± 0.026, respectively) relative to untreated WT T-cells (1.00 ± 0.124). In
comparison to proliferation levels of untreated PTPN2 SNP cells (10.2 ± 1.64), those treated
with 10 and 20 M of spermidine had a significant reduction in proliferation (2.04 ± 0.344 and
2.09 ± 0.231, respectively) (Figure 7A). A similar trend was seen for PTPN22 SNP cells, where
10 and 20 M of spermidine significantly reduced proliferation levels relative to untreated
PTPN22 SNP cells (2.71 ± 0.554, 0.703 ± 0.017, and 8.42 ± 0.896, respectively) (Figure 7B).
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Spermidine Decreases Pro-Inflammatory Cytokine Secretion in CRISPR-Cas9-edited Jurkat Tcells with PTPN2/22 SNPs
In Table 5, a fully automated ELISA was again used to evaluate pro-inflammatory
cytokine secretion levels in PHA-stimulated WT, PTPN2:rs478582-C, and PTPN22:rs2476601A SNP T-cells treated with spermidine (10 and 20 M). IFN- and TNF- levels in PHAstimulated WT T-cells with no spermidine treatment were 0.283 ± 0.026 pg/mL and 0.785 ±
0.012 pg/mL, respectively. Relative to these untreated controls, 10 and 20 M of spermidine
showed a significant reduction in IFN- secretion with 0.124 ± 0.005 pg/mL and 0.172 ± 0.010
pg/mL, respectively. Similarly, TNF- secretion levels were significantly reduced in response to
10 and 20 M of spermidine (0.359 ± 0.012 pg/mL and 0.353 ± 0.022 pg/mL, respectively).
PHA-stimulated PTPN2 SNP T-cells with no spermidine treatment IFN- and TNF- secretion
levels of 0.359 ± 0.020 pg/mL and 4.87 ± 0.292 pg/mL, respectively. Relative to these untreated
controls, 10 and 20 M of spermidine significantly reduced IFN- levels (0.115 ± 0.010 pg/mL
and 0.164 ± 0.006 pg/mL, respectively). The same was seen for TNF- levels with spermidine
treatment of 10 M (0.469 ± 0.015 pg/mL) and 20 M (0.484 ± 0.016 pg/mL). Untreated
PTPN22 SNP T-cells stimulated with PHA had IFN- secretion of 0.237 ± 0.009 pg/mL and
TNF- secretion of 10.8 ± 0.318 pg/mL. In comparison to these untreated controls, 10 M of
spermidine significantly reduced IFN- secretion (0.108 ± 0.010 pg/mL) as well as TNF-
secretion (0.609 ± 0.021 pg/mL). The same was seen for 20 M of spermidine where IFN-
secretion was 0.130 ± 0.010 and TNF- secretion was 0.408 ± 0.039 pg/mL.
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Spermidine Decreases T-cell Activation in CRISPR-Cas9-edited Jurkat T-cells with PTPN2/22
SNPs
Fluorescent immunostaining of CD-25 (IL-2RA) was used again to determine the effect
of 10 M of spermidine on activation of PHA-stimulated WT, PTPN2:rs478582-C, and
PTPN22:rs2476601-A SNP T-cells as seen in Figure 8. The results showed a significant
reduction in the number of cells expressing CD25 (IL-2RA) in the PTPN2 and PTPN22 SNP cell
groups upon spermidine treatment which indicates decreased T-cell activation levels (Figure 8).
In comparison to 80.32 ± 2.6% of untreated PTPN2 SNP cells expressing CD25, only 51.39 ±
0.6% of PTPN2 SNP cells treated with 10 M of spermidine expressed CD25. (Figure 8B).
Similarly, 46.36 ± 1.00% of spermidine treated PTPN22 SNP cells expressed CD25 as opposed
to 85.82 ± 0.8% of untreated PTPN22 SNP cells (Figure 8B). There was a decrease in CD-25
expressing cells in WT T-cells treated with spermidine (59.19 ± 1.9%) compared to untreated
WT T-cells (70.5 ± 1.4%), however, the difference was not significant (Figure 7,8).
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CHAPTER FOUR: DISCUSSION
As prevalence of inflammatory autoimmune diseases such as CD and RA continue to rise
across the globe, the burden of disease also increases making it crucial that we understand the
etiology and contributing factors to the pathogenesis of these disorders so improved diagnostics
can be developed and identified. Of added importance is the need for cheaper and safer
therapeutic agents, with fewer side effects, that are effective in patients with genetic
polymorphisms. Diagnosis of CD involves examination of clinical symptoms (abdominal pain,
diarrhea, fatigue, weakness, weight variations, and rectal bleeding) along with radiography,
endoscopy, colonoscopy, and sampling of the upper gastrointestinal tract [46]. However, in
severe cases and infection, diagnosis of CD is very difficult [46]. Current methods of diagnosis
for RA include examining effected joints in the body and the presence of autoantibodies such as
anti-cyclic citrullinated proteins (anti-CCP) and rheumatoid factor (RF) using serological blood
tests [15,47]. Early and accurate detection of CD and RA is crucial for patients to begin
treatment to prevent or significantly slow development of the diseases and their associated tissue
or organ damage. Since CD and RA are the result of a combination of environmental triggers and
genetic susceptibility, diagnostic measures should account for this and screen for genetic
polymorphisms that could influence patient response to treatments. Multiple studies have shown
genetically susceptible patients to either be more or less likely to respond to a number of
therapeutic agents or suffer from adverse events [48-52].
Our lab previously identified the PTPN2 SNP (rs478582-C) and the PTPN22 SNP
(rs2476601-A) as being significant in clinical samples of CD and RA [17-18]. Patient samples
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with these SNPs were found to have a loss of PTPN2/22 negative regulatory function and
increased inflammatory processes compared to normal, WT, patient samples [17-18]. This
intrigued us to investigate the inflammatory effects of these PTPN2/22 SNPs in vitro to confirm
and validate our previous findings in pure T-cell cultures without confounding variables that may
influence the observed response as seen in clinical samples. This study confirmed the proinflammatory effects of the PTPN2/22 SNPs in human T lymphocytes and evaluated the antiinflammatory effects of spermidine in normal cells and those with genetic anomalies. This was
achieved by using CRISPR-Cas9 to induce the PTPN2/22 SNPs in the genomic DNA of Jurkat
T-cells and measuring their effect on PTPN2/22 gene expression, T-cell proliferation, proinflammatory cytokine secretion, and T-cell activation, which are all reportedly effected in CD
and RA patients [12, 17-18, 30-31].

While further verification of the SNP region sequencing is pending, we presume to have
mixed cell cultures of WT and edited cells based on all the compiled results indicating increased
inflammatory responses in SNP cell groups. Thus, our findings of inflammation induced by the
PTPN2/22 SNPs may be of smaller magnitude compared to a pure culture of PTPN2/22 SNP
cells.

There has been extensive debate in the literature on the effect of PTPN2/22 SNPs on their
corresponding gene expression and function [16,53-55]. Our results showed that presence of the
PTPN2/22 SNPs resulted in a significant decrease in expression of their corresponding genes;
PTPN2 SNP cells had lower PTPN2 expression and PTPN22 SNP cells had lower PTPN22
expression compared to WT cells. This reduction could lead to loss of the negative regulatory
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function of PTPN2 and PTPN22. Furthermore, this decrease in PTPN2/22 expression in edited
T-cells was at a markedly greater reduction than our lab’s previous findings using clinical blood
samples from CD and RA patients. High T-cell proliferation levels also contribute to the
progressive inflammation associated with CD and RA [12,17-18,30-31]. Stimulation of edited Tcells with PHA resulted in a significantly greater proliferation response than in WT T-cells.
PTPN2 SNP cells had a 10.2-fold increase while PTPN22 SNP cells had an 8.4-fold increase.
This increase in proliferation was even greater than previous findings using clinical CD and RA
samples where there was only a 2.2-fold and 1.2-fold increase, respectively [17-18,56]. CD and
RA are also characterized by an increase in the pro-inflammatory cytokines IFN- and TNF-
[17-18,57]. In agreement with this, this study showed a significant increase in secretion of both
IFN- and TNF- in edited T-cells in comparison to WT T-cells. Lastly, CD and RA also consist
of hyperactive T-cells [12,17-18,30-31]. The most prominent marker of T-cell activation is
CD25 or IL-2RA which is the alpha chain of the trimeric IL-2 receptor on the surface of many
peripheral blood lymphocyte subsets [58]. Stimulation of the TCR complex by IL-2 or other
cytokines released by monocytes or macrophages activates T-cells leading to upregulation of
CD25 expression [58]. CD25 expression then triggers a signaling cascade that leads to
proliferation and survival of activated T-cells [58]. Our findings show a significant increase in
the number of T-cells expressing CD-25 (IL-2RA) on the cell surface in PTPN2 and PTPN22
SNP cell groups, thus indicating hyperactivity.

Our findings thus far confirmed that presence of PTPN2/22 SNPs leads to a lack of
negative feedback regulation resulting in hyperactive T-cells that have increased levels of
proliferation and pro-inflammatory cytokine secretion. Additionally, the effects seen in the
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aforementioned results were at a higher magnitude than those found in our lab previously using
clinical samples. This could be a result of using pure cell cultures that only vary in the induced
genetic SNPs rather than buffy coats collected from blood samples which contained multiple Tcell subpopulations and have a number of other variables influencing the response such as
varying diets or medications in the patients. Further research can investigate the effects of
PTPN2/22 SNPs on levels of anti-inflammatory cytokines like IL-6 and also confirm their role in
promoting inflammation due to a loss of negative regulatory function of PTPN2/22 by inducing
the SNPs in mice models.

A growing field of research is evaluating the anti-inflammatory properties of polyamines.
These compounds are found naturally in foods of plant origin such as legumes, soy derivatives,
mushrooms, spinach, cauliflower, green beans, citrus fruits, green peppers, and wheat germ [59].
They are also found in animal-derived foods like beef, chicken, fish, milk, eggs, and cheese [59].
Polyamines are known to be central to many pathways involved in cell proliferation, growth, and
death [59-61]. They are also essential for stabilizing DNA negative charges, RNA transcription,
protein synthesis, ion channel regulation, immune response regulation, and acting as an
antioxidant such as for free radical elimination [59]. Supplementation of polyamines has been
proven to promote longevity in a number of organisms including yeast, flies, worms, mice, and
human peripheral blood mononuclear cells (PBMCs) [60-63]. Polyamines also have a central
role in reestablishing the intestinal mucosa via proliferation and differentiation [60,64]. In
inflammatory disease models, spermidine was shown to have significant anti-inflammatory
effects making it a promising candidate for use as a therapeutic agent. It inhibited skin
inflammation and macrophage activation in mice, blocked NF-B and MAPK signaling
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pathways, reduced pro-inflammatory genes and cytokines expression, and modulated M1/M2
macrophage markers [43-44,65-66].

Our results showed spermidine treatment rescued PTPN2/22 function in T-cells with
PTPN2/22 SNPs. First, spermidine significantly increased PTPN2/22 expression in all cell types
(WT, PTPN2 SNP, and PTPN22 SNP) and this increase was in a dose-dependent manner for
edited T-cells where 20 M of spermidine resulted in a greater increase than 10 M. While WT
T-cell proliferation levels remained relatively constant with spermidine treatment, PTPN2 and
PTPN22 SNP T-cells displayed a significant reduction in proliferation levels when treated with
spermidine. In addition, spermidine treatment also significantly reduced secretion of IFN- and
TNF- across all cell types. Finally, although spermidine treatment did not significantly reduce
the number of WT cells expressing CD25, there was a significant reduction in PTPN2 and
PTPN22 SNP T-cells, indicating a substantial decrease in T-cell activation levels.

Overall, the above results show spermidine reverses the inflammation induced by the
disease associated PTPN2/22 SNPs, providing strong evidence for the consideration of
spermidine as a more effective therapeutic agent to treat inflammatory disorders such as CD and
RA. However, more research is needed to understand the exact mechanism by which polyamines
influence these responses as well as the safety and tolerability of long-term polyamine
supplementation.
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APPENDIX A: FIGURES
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Identical = black

Different = red

PTPN22 SNP Cells

4
GTCGCAGGCACGTATGAGCCGCAT–CTTCGACAACGCGCAAATTGT- - - GCTTCTTGGCGATTGAGATG ATC GCGTC–CA
WT PTPN22 Gene Seq. 44,957 GTAGCTGGGAC–TACAAG–CGCATGCCACCACACCTGGCT AATTTTTTAACTTTTT G - - - - TTGAGATG - - - GGGTCTCA

78
45,027

PTPN22 SNP Cells

79
TAT–CTGCCGCGCGACCGGC - - - - - - GAAATGCACCGGCATGATGGCG– –CGAGTACGCGGCGTGATAGCCTTTTCAATC
45,028 TATGTTGCC - - - - - - CAGGC TGGTCTGAAAT TC - - - - - - - - - - TTGCG T TCAA - - - - - - - - - GTGAT - - - CTTT- - - - CC

149
45,075

150
GCGGTCA–CATCGATGCAGAGCGACTCTGCGCTCACGTCGACGAATACCGG–ATGAGC - - - - - - GCCCAGATA - - - - TCG
45,076 GC– CTCAGCCTC- - - C CAAAGTG - - - CTG - - - - - - - - - - - - GGATTACAGGCATGAGCCACTGAGTCCAGCCAGCCCTCC

217
45,136

WT PTPN22 Gene Seq.
PTPN22 SNP Cells
WT PTPN22 Gene Seq.
PTPN22 SNP Cells
WT PTPN22 Gene Seq.

218
GATGACTTCGGCCGTAGC–GGTGAAAGTGTGGGATG 252
45,137 CCT T TTTTTGG - - GTATCTAGAGAAA– TA TGGAATG 45,169

Length:
Identity:
Gaps:

276
141/276 (51.09%)
90/276 (32.61%)

Figure 1: Alignment of PTPN22 SNP region in CRISPR-Cas9-edited Jurkat T-cells with
PTPN22 SNP to Wild-type PTPN22 SNP region.

A) PTPN2 Expression

B) PTPN22 Expression

Figure 2: Effect of PTPN2/22 SNPs on their corresponding gene expression in CRISPR-Cas9edited Jurkat T-cells.
*p<0.05.
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A) WT vs. PTPN2 SNP T-cells

B) WT vs. PTPN22 SNP T-cells

Figure 3: Effect of PTPN2/22 SNPs on proliferation in CRISPR-Cas9-edited Jurkat T-cells
stimulated with PHA.
*p<0.001.
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Figure 4: Effect of PTPN2/22 SNPS on CD25 (IL-2RA) expression in CRISPR-Cas9-edited
Jurkat T-cells stimulated with PHA.
*p<0.05.
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Figure 5: Effect of spermidine on PTPN2 expression in WT and PTPN2 SNP T-cells stimulated
with PHA
*p<0.05 compared to unstimulated and untreated cells for each cell type. †p<0.05 compared to
unstimulated with 10 µM SPD for each cell type. **p<0.05 compared to PHA-stimulated and
untreated cells for each cell type. ††p<0.05 compared to PHA-stimulated with 10 µM SPD for
each cell type.

Figure 6:Effect of spermidine on PTPN22 expression in WT and PTPN22 SNP T-cells
stimulated with PHA
*p<0.05 compared to unstimulated and untreated cells for each cell type. †p<0.05 compared to
unstimulated with 10 µM SPD for each cell type. **p<0.05 compared to PHA-stimulated and
untreated cells for each cell type. ††p<0.05 compared to PHA-stimulated with 10 µM SPD for
each cell type.
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A) WT vs. PTPN2 SNP T-cells

B) WT vs. PTPN22 SNP T-cells

Figure 7: Effect of spermidine on proliferation in CRISPR-Cas9-edited Jurkat T-cells stimulated
with PHA.
*p<0.05.
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Figure 8: Effect of spermidine on CD25 (IL-2RA) expression in CRISPR-Cas9-edited Jurkat Tcells stimulated with PHA.
*p<0.05.
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Table 1: List of SNPs examined in this study.
Gene

RS#

Mutation

Location

Mutation Phenotype

Reference

PTPN2

rs478582

T>C

Intron 3

High susceptibility to RA, TID,
MS, and Celiac disease

38

PTPN22

rs2476601

G>A

R620W

High susceptibility to CD, RA,
TID, MS, SLE, and Celiac disease

42

NCBI was used to obtain gene mutation and location information [45].
R = arginine, W = tryptophan, AA = amino acid, CD = Crohn’s disease, RA = rheumatoid arthritis, TID = type I diabetes,
MS = multiple sclerosis, SLE = systemic lupus erythematosus
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Table 2: Synthetic single-guide RNA and donor DNA sequences
Gene

Sequence
(5’ → 3’)
AUUAUACUACGUCAAUUCAC
+ scaffold

Component
sgRNA

PTPN2
Donor DNA

CTACCTCAAGTAAAAAATGCATTTTAGTTTCCTGTGAATT
GACGCAGTATAATAGCTCATAGTTACATTAATCTGCATAT
(80 bases)

Donor DNA reverse complement

ATATGCAGATTAATGTAACTATGAGCTATTATACTGCGTC
AATTCACAGGAAACTAAAATGCATTTTTTACTTGAGGTAG
(80 bases)

Forward PCR Primer

CAGGGCTGTCTTTCCCCCTA (20 bases)

Reverse PCR Primer

GCAAAGTGTCCACCTTTGAT (20 bases)

sgRNA

AAUGAUUCAGGUGUCCGUAC
+ scaffold

Donor DNA

AGCTTCCTCAACCACAATAAATGATTCAGGTGTCC
TACAGGAAGTGGAGGGGGGATTTCATCATCTATCC
(70 bases)

Donor DNA reverse complement

GGATAGATGATGAAATCCCCCCTCCACTTCCTGTA
GGACACCTGAATCATTTATTGTGGTTGAGGAAGCT
(70 bases)

Forward PCR Primer

CGCCCAGCCCTACTTTTGAG (20 bases)

Reverse PCR Primer

CCATGCCCATCCCACACTTT (20 bases)

PTPN22
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Table 3: RT-qPCR primer sequences for tested genes
Gene

Forward Primer Sequence
(5’ → 3’)

Reverse Primer Sequence
(5’ → 3’)

GAPDH

5’-CTTTTGCAGACCACAGTCCATG-3’
(22 bases)

5’-TTTTCTAGACGGCAGGTCAGG-3’
(21 bases)

PTPN2

5’-CTAGAGGGTTAGCGAGCCTCA-3’
(21 bases)

5’- TCATGTGGGAATGATTTTTGGTCAC-3’
(25 bases)

PTPN22

5’-TAGTTTTATTTGCAGGTGTACTTGCAG-3’
(27 bases)

5’-TGGTCAAGATGCTGCCTAACATT-3’
(23 bases)

Table 4: Effect of PTPN2/22 SNPs on IFN- and TNF- secretion in CRISPR-Cas9-edited Jurkat T-cells stimulated with PHA
Cell Group

[IFN-γ] ± SD
(pg/mL)

[TNF-] ± SD
(pg/mL)

WT

0.029  0.003

0.293 ± 0.042

PTPN2 (TT → CC)

0.060  0.004*

0.507 ± 0.014*

PTPN22 (GG → AA)

0.054  0.002*

0.408 ± 0.039*

*p<0.05
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Table 5: Effect of spermidine on IFN- and TNF- secretion in CRISPR-Cas9-edited Jurkat Tcells stimulated with PHA.
Treatment

Spermidine
Concentration (M)

[IFN-γ] ± SD
(pg/mL)

[TNF-a] ± SD
(pg/mL)

WT

-

0.029  0.003

0.293  0.042

-

0.283  0.026

0.785  0.012

10

0.124  0.005*

0.359  0.012**

20

0.172  0.010*

0.353  0.022**

-

0.060  0.004

0.408  0.039

-

0.359  0.020

4.87  0.292

10

0.115  0.010*

0.469  0.015**

20

0.164  0.006*

0.484  0.016**

-

0.054  0.002

0.507  0.014

-

0.237  0.009

10.8  0.318

10

0.108  0.010*

0.609  0.021**

20

0.130  0.010*

0.408  0.039**

WT+PHA

PTPN2

PTPN2+PHA

PTPN22

PTPN22+PHA
*p<0.05
**p<0.0001
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